285 related articles for article (PubMed ID: 34875405)
1. Safety and Efficacy of Prophylactic Levofloxacin in Pediatric and Adult Hematopoietic Stem Cell Transplantation Patients.
Gardner JC; Courter JD; Dandoy CE; Davies SM; Teusink-Cross A
Transplant Cell Ther; 2022 Mar; 28(3):167.e1-167.e5. PubMed ID: 34875405
[TBL] [Abstract][Full Text] [Related]
2. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Satlin MJ; Vardhana S; Soave R; Shore TB; Mark TM; Jacobs SE; Walsh TJ; Gergis U
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1808-14. PubMed ID: 26150022
[TBL] [Abstract][Full Text] [Related]
3. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
Alexander S; Fisher BT; Gaur AH; Dvorak CC; Villa Luna D; Dang H; Chen L; Green M; Nieder ML; Fisher B; Bailey LC; Wiernikowski J; Sung L;
JAMA; 2018 Sep; 320(10):995-1004. PubMed ID: 30208456
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Febrile Neutropenia in Autologous Hematopoietic Stem Cell Transplant (HSCT) Recipients on levofloxacin prophylaxis.
Signorelli J; Zimmer A; Liewer S; Shostrom VK; Freifeld A
Transpl Infect Dis; 2020 Apr; 22(2):e13225. PubMed ID: 31785022
[TBL] [Abstract][Full Text] [Related]
5. Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence.
Wang CH; Chang FY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2018 Feb; 51(1):123-131. PubMed ID: 27103500
[TBL] [Abstract][Full Text] [Related]
6. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial prophylaxis and the rate of blood stream infections and Clostridioides difficile in pediatric stem cell transplantation: A single-center retrospective study.
Alrugaib T; Alsultan A; Elbashir E; Albdah B; Alharbi M; Essa MF
Pediatr Transplant; 2023 Feb; 27(1):e14375. PubMed ID: 35946349
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the rates of Clostridium difficile and bacteremia after delaying fluoroquinolone prophylaxis from day 0 to day +3 post autologous stem cell transplantation.
Koseck K; Steinberg A; Caliendo G; Meyer J; Kim SS
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28456140
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients.
Ziegler M; Landsburg D; Pegues D; Bilker W; Gilmar C; Kucharczuk C; Gorman T; Bink K; Moore A; Fitzpatrick R; Stadtmauer EA; Mangan P; Kraus K; Han JH
Biol Blood Marrow Transplant; 2019 May; 25(5):1004-1010. PubMed ID: 30481595
[TBL] [Abstract][Full Text] [Related]
10. Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow-up for impact on health care-associated infections.
Davis A; Stevens AM; Brackett J; Marquez L; Foster CE; Sauer HE; Campbell JR
Pediatr Blood Cancer; 2022 Jul; 69(7):e29525. PubMed ID: 35029328
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough viridans streptococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients receiving levofloxacin prophylaxis in a Japanese hospital.
Kimura M; Araoka H; Yoshida A; Yamamoto H; Abe M; Okamoto Y; Yuasa M; Kaji D; Kageyama K; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Asano-Mori Y; Uchida N; Hishinuma A; Izutsu K; Wake A; Taniguchi S; Yoneyama A
BMC Infect Dis; 2016 Aug; 16():372. PubMed ID: 27495798
[TBL] [Abstract][Full Text] [Related]
12. Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem-cell transplantation.
Copeland V; McLaughlin M; Trifilio S
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29080369
[TBL] [Abstract][Full Text] [Related]
13. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
Willems L; Porcher R; Lafaurie M; Casin I; Robin M; Xhaard A; Andreoli AL; Rodriguez-Otero P; Dhedin N; Socié G; Ribaud P; Peffault de Latour R
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1295-301. PubMed ID: 22387347
[TBL] [Abstract][Full Text] [Related]
14. Incidence, risk factors, and outcome of blood stream infections during the first 100 days post-pediatric allogeneic and autologous hematopoietic stem cell transplantations.
Youssef A; Hafez H; Madney Y; Elanany M; Hassanain O; Lehmann LE; El Haddad A
Pediatr Transplant; 2020 Feb; 24(1):e13610. PubMed ID: 31682054
[TBL] [Abstract][Full Text] [Related]
15. Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation.
Zając-Spychała O; Wachowiak J; Pieczonka A; Siewiera K; Frączkiewicz J; Kałwak K; Gorczyńska E; Chybicka A; Czyżewski K; Jachna-Sawicka K; Wysocki M; Klepacka J; Goździk J; Zaucha-Prażmo A; Kowalczyk JR; Styczyński J
Transpl Infect Dis; 2016 Oct; 18(5):690-698. PubMed ID: 27479544
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.
Jandial A; Lad D; Jain A; Khadwal A; Singh C; Prakash G; Suri V; Sreedharanunni S; Sachdeva MUS; Ray P; Varma N; Varma S; Malhotra P
Transpl Infect Dis; 2023 Oct; 25(5):e14123. PubMed ID: 37573150
[TBL] [Abstract][Full Text] [Related]
17. Impact of anti-anaerobic antibiotic activity on graft-versus-host disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients at an institution that utilizes antibiotic cycling.
Hanks CR; Slain D; Kanate AS; Wen S; Cumpston A
Transpl Infect Dis; 2021 Aug; 23(4):e13676. PubMed ID: 34165853
[TBL] [Abstract][Full Text] [Related]
18. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline.
Therriault BL; Wilson JW; Barreto JN; Estes LL
Mayo Clin Proc; 2010 Aug; 85(8):711-8. PubMed ID: 20675508
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.
Drayson MT; Bowcock S; Planche T; Iqbal G; Pratt G; Yong K; Wood J; Raynes K; Higgins H; Dawkins B; Meads D; Hulme CT; Whittaker AC; Hawkey P; Low E; Dunn JA
Health Technol Assess; 2019 Nov; 23(62):1-94. PubMed ID: 31690402
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.
Blennow O; Ljungman P; Sparrelid E; Mattsson J; Remberger M
Transpl Infect Dis; 2014 Feb; 16(1):106-14. PubMed ID: 24372809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
